Alphamab Oncology (STU:3NK) ROE % Adjusted to Book Value : -4.18% (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology ROE % Adjusted to Book Value?

Alphamab Oncology's ROE % for the quarter that ended in Jun. 2024 was -5.43%. Alphamab Oncology's PB Ratio for the quarter that ended in Jun. 2024 was 1.30. Alphamab Oncology's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was -4.18%.

Alphamab Oncology ROE % Adjusted to Book Value Historical Data

The historical data trend for Alphamab Oncology's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology ROE % Adjusted to Book Value Chart

Alphamab Oncology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-3.19

-4.10

-3.28

-3.83

5.33

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial										-3.72	-1.35	-5.83	-4.18	13.42

Competitive Comparison of Alphamab Oncology's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Alphamab Oncology's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alphamab Oncology's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Alphamab Oncology ROE % Adjusted to Book Value Calculation

Alphamab Oncology's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-12.71%	/	3.32
	=	-3.83%

Alphamab Oncology's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-5.43%	/	1.30
	=	-4.18%

Alphamab Oncology ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (STU:3NK) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

09966:Hong Kong

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.

Alphamab Oncology Headlines

No Headlines